Telma Lopes

Bio: Telma Lopes is an academic researcher. The author has an hindex of 3, co-authored 3 publications receiving 19 citations.

[Pulmonary epithelioid hemangioendothelioma - rarity, diagnosis and treatment difficulties].

Abstract: The authors report a case of a primary pulmonary epithelioid haemangioendothelioma (EHE) in a 51 year-old man, a mechanic, who complained of a dry cough followed by constitutional symptoms and dyspnoea. Patient underwent a series of diagnostic exams including surgical biopsy and pulmonary tuberculosis was diagnosed. He was prescribed tuberculosis drugs for three weeks. Following clinical and imagiology deterioration, the case was reviewed by pathologists who concluded the pulmonary biopsy revealed an intermediate/high grade pulmonary EHE/angiosarcoma. The patient underwent three cycles of chemotherapy with carboplatin, etoposide and bevacizumab with no complications. He died seven months after onset of symptoms and seven weeks after definitive diagnosis. The authors wish to highlight the rarity of this pulmonary neoplasm and the importance of clinical suspicion, and the diagnosis and treatment difficulties in addition to the potential benefits of antiangiogenic drugs.

Hemangioendotelioma epitelióide do pulmão - Raridade, dificuldades diagnósticas e terapéutica

Abstract: Resumo Os autores apresentam um caso de hemangioendotelioma epitelioide (HEE) primario do pulmao num doente de 51 anos, sexo masculino, que iniciou queixas de tosse seca, seguida de sintomas constitucionais e dispneia. Apos realizacao de alguns exames complementares de diagnostico, que incluiram biopsia cirurgica, foi considerada a hipotese de tuberculose pulmonar e iniciou antibacilares, que manteve durante tres semanas. Por agravamento clinico e imagiologico, foi feita revisao do caso e estudo imunoistoquimico dos tecidos pulmonares biopsados e concluiu-se estar perante um HEE de alto grau/angiossarcoma do pulmao. Iniciou quimioterapia com carboplatina, etoposido e bevacizumab, com ligeira melhoria. Faleceu sete meses apos o aparecimento dos primeiros sintomas e sete semanas apos o diagnostico definitivo. Os autores pretendem realcar a raridade desta neoplasia pulmonar, a importância da suspeicao clinica e as dificuldades no diagnostico e tratamento, e salientar os potenciais beneficios da utilizacao de um farmaco antiangiogenico.

Hemangioendotelioma epitelióide do pulmão - Raridade, dificuldades diagnósticas e terapêutica Pulmonary epithelioid hemangioendothelioma - Rarity, diagnosis and treatment difficulties

Abstract: Resumo Os autores apresentam um caso de hemangioendotelioma epitelioide (HEE) primario do pulmao num doente de 51 anos, sexo masculino, que iniciou queixas de tosse seca, seguida de sintomas constitucionais e dispneia. Apos realizacao de alguns exames complementares de diagnostico, que incluiram biopsia cirurgica, foi considerada a hipotese de tuberculose pulmonar e iniciou antibacilares, que manteve durante tres semanas. Por agravamento clinico e imagiologico, foi feita revisao do caso e estudo imunoistoquimico

Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma—a suitable treatment option: case report and review of anti-angiogenic treatment options

Abstract: Epithelioid hemangioendothelioma is a rare vascular tumor of borderline or low-grade malignancy. The lungs and liver are the two common primary organs affected. Metastatic disease was reported in more than 100 cases in the literature. However, no firm conclusions can be determined for recommended treatment options. The current case presents a patient with metastatic pulmonary epithelioid hemangioendothelioma to the cervical and mediastinal lymph nodes, lungs and liver that has been treated with pazopanib for more than two years with PET avid complete metabolic response in the mediastinum and lungs, and long-lasting stable disease. Target therapies that block VEGFR have a logical base in this rare malignancy. The current case is the first to report objective, long-lasting response to pazopanib.

Treatment of pulmonary epithelioid hemangioendothelioma with combination chemotherapy: Report of three cases and review of the literature

Abstract: No standard therapy for pulmonary epithelioid hemangioendothelioma (PEH) has yet been established due to the rarity of the disease, the lack of clear standards for treatment and the partial-to-complete spontaneous regression. This report describes three cases of PHE manifested as bilateral intrapulmonary masses with an initial diagnosis conducted by thoracoscopic lung biopsy. These patients demonstrated a partial response to combination chemotherapy with carboplatin, paclitaxel, bevacizumab or endostar, and an improvement in clinical status. Furthermore, we reviewed the literature regarding such patients who received chemotherapy and immunotherapy; this indicated that patients with PEH demonstrated a good partial response to chemotherapy with carboplatin, paclitaxel, bevacizumab, thalidomide and α-interferon. Overall, combination chemotherapy regimens may hold therapeutic potential for the treatment of this rare disease.

Primary lung neoplasms presenting as multiple synchronous lung nodules

Abstract: Multiple synchronous lung nodules are frequently encountered on computed tomography (CT) scanning of the chest and are most commonly either non-neoplastic or metastases from a known primary malignancy. The finding may initiate a search for primary malignancy elsewhere in the body. An exception to this rule, however, is a class of rare primary lung neoplasms that originate from epithelial (pneumocytes and neuroendocrine), mesenchymal (vascular and meningothelial) and lymphoid tissues of the lung. While these rare neoplasms also present as multiple synchronous unilateral or bilateral lung nodules on chest CT, they are often overlooked in favour of more common causes of multiple lung nodules. The correct diagnosis may be suggested by a multidisciplinary team and established on biopsy, performed either as part of routine diagnostic work-up or staging for malignancy. In this review, we discuss clinical presentations, imaging features, pathology findings and subsequent management of these rare primary neoplasms of the lung.